channel:@VeevaSystems
7 videos
Season 1 Episode 6: Improving the Customer Experience through Medical-Commercial Collaboration
Veeva Systems Inc
@VeevaSystems
Oct 3, 2025
This video explores the critical importance of medical-commercial collaboration within the pharmaceutical industry to enhance the customer (HCP) experience and drive better patient outcomes. Industry leaders from UCB and Takeda discuss the challenges of traditional silos, the strategic imperative for integrated efforts in product launches, and the pivotal role of technology, data, and AI in fostering a more unified and effective future for healthcare engagement. Key Takeaways: * **Essential Cross-Functional Collaboration:** Effective medical-commercial-clinical collaboration is paramount for successful product launches, optimizing HCP engagement, and ultimately improving patient outcomes. A lack of coordination leads to inefficiencies, missed opportunities, and confusion among healthcare providers. * **Technology as an Integration Enabler:** Platforms like Veeva CRM, Veeva Vault, Veeva Link Key People, and Veeva Link Workflow are crucial for creating transparency around HCP engagements, centralizing approved medical content, and facilitating coordinated cross-functional planning. * **AI Augments, Data Foundations Enable:** While AI, particularly Generative AI, is recognized as a powerful tool to augment medical affairs by optimizing tasks and enhancing insight detection, a robust data foundation (including data governance, standards, and management) is critical for its successful implementation and for deriving actionable insights. * **Change Management is Key to Adoption:** Successful implementation of integrated processes and technologies requires strong senior leadership buy-in, early and continuous engagement with all stakeholders (including compliance and legal), and a phased approach to manage change fatigue and ensure end-user adoption. * **Measuring Impact through Data:** Increased adoption of integrated systems provides the necessary data to measure operational effectiveness, engagement quality, and insights gathering, which are foundational steps towards ultimately assessing and improving medical affairs' impact on patient outcomes and clinical practice.
Episode 6: Data Managers: Driving the Future of Clinical Research
Veeva Systems Inc
/@VeevaSystems
Dec 2, 2022
This video directly addresses the evolving landscape of clinical data management within the pharmaceutical industry, the strategic importance of data, and the increasing role of advanced technologies like AI/ML. This video explores the transformative journey of clinical data management, highlighting its shift from a back-office function to a strategic imperative driving the future of clinical research. Richard Young and Mayank Anand discuss how data professionals' roles are evolving in an era of decentralized data, emphasizing the critical need for data to optimize trial protocols, operations, and patient access to treatments. The conversation delves into GSK's innovative approach to data strategy and management, which integrates various data functions and prioritizes an enterprise mindset, stakeholder collaboration, and patient-centricity. A key theme is the operationalization of AI/ML in clinical research, moving beyond buzzwords to real-world applications, while also considering ethical implications and the need for continuous professional evolution. Key Takeaways: * **Strategic Elevation of Data Management:** Clinical data management is no longer a secondary function but is now "front and center" in optimizing clinical trials, requiring professionals to drive the future of research rather than just support it. * **AI/ML as an Operational Reality:** AI and Machine Learning are no longer just buzzwords but are becoming integral to clinical data management, offering significant opportunities for efficiency and transformation, necessitating discussions around ethical AI and regulatory alignment. * **Integrated Data Strategy for End-to-End Oversight:** Leading pharmaceutical companies like GSK are adopting a holistic "Data Strategy and Management" approach, consolidating functions such as data acquisition, medical coding, core data management, centralized monitoring, and data analytics to ensure comprehensive and strategic data oversight. * **Enterprise Mindset and Collaborative Innovation:** Successful data transformation requires an "enterprise mindset" that considers all stakeholders (clinical operations, biostats, pharmacovigilance, etc.) and fosters collective ownership, utilizing agile methodologies to accelerate delivery and manage complex interdependencies. * **"Total Experience" for Adoption and Impact:** Designing new technologies and processes with "Total Experience" (TX) in mind—encompassing change management, communication, and the impact on all end-users, including patients and investigators—is crucial for successful adoption and achieving desired outcomes. * **Evolving Role of Data Professionals:** The traditional "data manager" role is transforming into future-oriented positions like "data scientist" or "data engineer," emphasizing continuous learning and adaptation to new technologies, rather than fearing job displacement by AI. * **Challenges in Infrastructure and Data Democratization:** Significant industry challenges persist in modernizing legacy infrastructure and achieving broader data democratization, highlighting areas for future innovation and collaborative efforts to unlock the full potential of clinical data.
Season 1 Episode 5: Turning Content into Memorable Customer Experiences
Veeva Systems Inc
@VeevaSystems
Jun 6, 2025
This video, featuring marketing leaders from Genentech and hosted by Veeva, explores the critical transformation from content creation to delivering memorable customer experiences within the life sciences industry. The discussion highlights the strategic shift required for pharmaceutical companies to move beyond product-centric marketing to a more holistic, personalized, and data-driven approach. Key themes include the necessity of organizational change, the pivotal role of real-time data in shaping and optimizing customer interactions, and the imperative to foster a culture of continuous experimentation and rapid content iteration to meet evolving customer demands and competitive pressures. Key Takeaways: * **Evolution of Pharma Marketing:** The industry is moving from a product-first, brand-oriented approach to a holistic, experience-driven marketing discipline that unifies content and customer experience, driven by increasing competition and customer demands for better healthcare experiences. * **Content vs. Experience:** Content is necessary but not sufficient; true customer experience is built on deep customer understanding and personalization, akin to transforming a "house" (content) into a "home" (experience). This requires breaking down silos between content creation, experience delivery, and measurement. * **Organizational Transformation Drivers:** Successful change requires full senior leadership commitment, a clear vision, addressing discomfort with the status quo, and crucially, aligning incentive structures to support new ways of working and moving away from outdated processes. Leaders must be prepared to "blow up the old bridge" to fully embrace new methodologies. * **Data as the Core Enabler:** Real-time data from every customer engagement (or lack thereof) is fundamental for crafting effective messages, optimizing content, and informing strategic adjustments. This necessitates integrated MarTech platforms and a robust content supply chain to provide a holistic view of performance. * **Embrace Experimentation and Speed:** The industry must stop "planning to perfection" and instead embrace continuous experimentation, rapid iteration, and a willingness to put out "90% right" content, measuring and optimizing constantly to adapt to fast-changing technology and consumer behavior. * **Redefining Customer Engagement:** The traditional view of the sales representative as the sole "quarterback" of the customer relationship is evolving. A multi-channel approach is needed, recognizing a diverse web of decision-makers (including patients and caregivers) beyond just the prescriber. * **Future of Content:** The goal is to create significantly more engaging, personalized content (e.g., "20x the content") at scale, faster, and more affordably, with integrated, real-time measurement feeding back into content generation.
2019 Veeva R&D Summit Keynote: Veeva Vision
Veeva Systems Inc
/@VeevaSystems
Sep 12, 2019
This.ai offers specialized consulting. The discussion of clinical data management, regulatory compliance (e.g. This video explores Veeva's vision for an integrated "Development Cloud" for the life sciences R&D sector, delivered through a keynote address at their 2019 R&D Summit. The speaker outlines Veeva's core vision to build an industry-specific cloud for life sciences, encompassing applications, data, professional services, and an ecosystem of partners, all aimed at improving and extending human life. Key themes include Veeva's foundational values ("do the right thing," customer success, employee success, speed) and significant product innovations across various R&D domains. The presentation details advancements in clinical data management (e.g., agile study design, autosave), the introduction of Vault Safety for pharmacovigilance, and the development of "Safety AI" to automate the processing of unstructured safety content. Other innovations include continuous publishing for regulatory submissions, enhanced collaborative authoring capabilities through Microsoft Word integration, and a complete quality suite (Quality Docs, QMS, Training). The speaker emphasizes the importance of integration via "Spark" technology to connect various Vaults and external systems, and the necessity for customers to embrace business process changes alongside new technology adoption. Key Takeaways: * **Integrated Development Cloud Strategy:** Veeva is pursuing a comprehensive "Development Cloud" strategy, aiming to provide an integrated suite of modular applications that serve as the "operating system for drug development," covering clinical, safety, regulatory, and quality functions to break down silos. * **Strategic AI Investment in Pharmacovigilance:** Veeva is making a significant move into AI with "Safety AI," a specialized product designed to process unstructured content (PDFs, emails, text) using an AI engine to generate review-ready safety cases, addressing a complex and error-prone area in pharmacovigilance. * **Focus on Continuous and Incremental Innovation:** The company emphasizes "reimagining" existing processes and delivering incremental improvements (e.g., agile study design, quick view, autosave in clinical data management, continuous publishing) to enhance efficiency, user experience, and adaptability to evolving industry needs like frequent protocol amendments. * **Modernizing Regulatory and Content Management:** Innovations like "Vault Publishing" with continuous publishing capabilities for eCTD formats and tight integration with Microsoft Word for collaborative authoring demonstrate a strong commitment to streamlining regulatory submission processes and improving content management within a compliant framework. * **Importance of Integration and Ecosystem:** Veeva's "Spark" integration technology is critical for connecting various Vault applications and external systems, facilitating seamless data flow and business processes across the entire R&D lifecycle, and enabling a more unified operational environment. * **Business Process Transformation is Key:** The speaker explicitly highlights that adopting new technologies, particularly transformative ones like continuous publishing, necessitates significant changes in business processes and roles, underscoring that technology implementation is not merely a tool adoption but a fundamental shift in operations.
SCRS Talks: Connecting Patients, Sites, and Sponsors to Improve Clinical Trials
Veeva Systems Inc
/@VeevaSystems
Jul 23, 2020
This. ai provides. This video explores the pressing challenges faced by patients, research sites, and sponsors in clinical trials, particularly exacerbated by the COVID-19 pandemic. Bree Burks from Veeva Systems highlights the industry's struggle with disparate systems and processes that limit data sharing and collaboration, leading to increased patient burden, financial instability for sites, and inefficiencies in drug development for sponsors. The discussion emphasizes the critical need for a more connected and patient-centric approach, advocating for technology that empowers rather than replaces research sites. Veeva's strategy to build a unified platform for the entire clinical trial ecosystem, including dedicated solutions for sites and patients, is presented as a key opportunity for improvement. Key Takeaways: * **Fragmented Clinical Trial Ecosystem:** The industry suffers from a lack of technological connectivity and data sharing between patients, research sites, and sponsors, leading to significant operational inefficiencies and increased burden across all stakeholders. * **Shift to Patient-Centricity and Site Empowerment:** There's an urgent need to design clinical trials with patient experience in mind and to empower research sites with integrated technology solutions, moving away from the concept of "site-less trials" towards "technology-empowered sites." * **Platform Approach to Technology:** Research sites should strategically evaluate technology partners that offer a unified, integrated platform rather than managing numerous disparate point solutions, which often leads to costly and complex integration challenges. * **Veeva's Expanding Clinical Trial Ecosystem:** Veeva is actively expanding its offerings beyond sponsors and CROs to include purpose-built, seamlessly integrated technology for research sites and patients, aiming to create a comprehensive, connected platform for the entire clinical trial lifecycle. * **Regulatory Compliance as a Core Feature:** Technology solutions for clinical trials must inherently address stringent regulatory requirements, with providers like Veeva explicitly offering 21 CFR Part 11 compliant tools to streamline operations while ensuring adherence. * **Strategic Technology Partnership for Sites:** Sites are advised to seek long-term technology partners that understand their complex needs, align with their vision, and can provide evolving, integrated solutions, rather than focusing solely on current features.
CTMS Oversight Deep Dive Demo
Veeva Systems Inc
/@VeevaSystems
Mar 22, 2022
This video provides a deep dive into Veeva Vault CTMS, showcasing its capabilities for comprehensive clinical trial oversight. It highlights how the platform facilitates effective collaboration, streamlines negotiations with CRO partners, and ensures regulatory compliance. The demonstration covers integrated study management, from initial planning and site activation to ongoing monitoring, risk assessment, and issue resolution. A central theme is the seamless integration between CTMS and TMF components, ensuring all clinical activities and documentation are managed within a unified, compliant system. The video also emphasizes robust data tracking, automated processes, and advanced reporting for real-time insights into study progress, site performance, and CRO oversight. Key Takeaways: * **Integrated Clinical Operations & Compliance:** Veeva Vault CTMS provides a unified platform for managing clinical trials, integrating CTMS and TMF functionalities to ensure seamless document management, regulatory compliance (e.g., 21 CFR Part 11 for signatures, automatic TMF artifact creation), and inspection readiness. * **Enhanced CRO and Vendor Oversight:** The system offers robust tools for managing and collaborating with CROs, including a global personnel directory for access control, automated notifications for CRO-submitted data (e.g., trip reports), dedicated issue logging against CROs, and dashboards for tracking vendor performance and issue resolution times.ai to offer AI-powered enhancements for predictive CRO performance, automated contract compliance checks, or intelligent issue triage. * **Proactive Risk Management & Issue Resolution:** The platform supports templatized risk assessments with automated scoring and integrated mitigation plans. It also provides comprehensive issue management capabilities, allowing for logging, assignment (including to CROs), tracking of resolution times, and trending analysis of quality findings and protocol deviations.ai could leverage AI/LLMs to enhance risk prediction, suggest optimal mitigation strategies, or automate the generation of issue summaries. * **Data-Driven Decision Making & Business Intelligence:** Extensive reporting and dashboard features provide real-time visibility into study progress, enrollment metrics, site performance, and TMF completeness. This enables data-driven decision-making, identification of at-risk milestones, and comparative analysis of CRO performance. * **Streamlined Workflow Automation:** The system automates several critical workflows, such as subject data calculation for actuals, automatic completion of milestones, generation of risk assessment documents, and creation of Part 11 compliant trip reports, significantly reducing manual effort and enhancing efficiency.
Simplifying Role-based Readiness
Veeva Systems Inc
/@VeevaSystems
Jul 13, 2017
This video explores how Veeva Vault QualityDocs simplifies role-based readiness and training for regulated documents within the life sciences industry. The speaker demonstrates how users can easily complete "read and understood" training tasks via email or a personalized home screen, ensuring 21 CFR Part 11 compliant electronic signatures. Managers can leverage built-in, point-and-click reporting and dashboarding tools to gain a 50,000-foot view of training compliance across users, job roles, and specific documents. The discussion also highlights Veeva Vault's capabilities as a digital asset library, supporting various content types including video for training, and its open API for integration with external Learning Management Systems (LMS) to facilitate more advanced, Level 2 training. The overarching theme is the platform's ability to combine ease-of-use with robust compliance for quality processes in regulated environments. Key Takeaways: * **Regulated Content Management Foundation:** Veeva Vault is presented as a purpose-built platform for the life sciences, offering inherent productivity and compliance features (e.g., 21 CFR Part 11 signatures, audit trails) for managing regulated content, including GxP documents. * **Streamlined "Read and Understood" Workflows:** The system automates the assignment, notification, and completion of training tasks, allowing users to easily access and acknowledge documents, thereby enhancing training compliance and operational efficiency. * **Powerful Compliance Reporting & Dashboards:** Veeva Vault provides intuitive, configurable reporting and dashboarding tools that enable managers to quickly track training compliance by individual, job role, or document, offering immediate insights into readiness and potential gaps. * **LMS Integration Capabilities:** The platform supports integration with external Learning Management Systems (LMS) via an open API, allowing for the extension of basic "read and understood" training to more complex Level 2 training (e.g., quizzes, curriculums) while maintaining a comprehensive audit trail. * **Versatile Digital Asset Support:** Veeva Vault functions as a digital asset library, capable of handling and rendering diverse training materials, including video, directly within the browser, offering flexibility in content delivery. * **Reduced Validation Burden:** As a multi-tenant cloud-based solution, Veeva Vault minimizes the implementation and upgrade burden, particularly by assisting with validation efforts (e.g., OQ), which is a significant advantage for regulated pharmaceutical and life sciences companies.